Recursion Pharmaceuticals Inc (RXRX) — Financial Flexibility Index
Recursion Pharmaceuticals Inc (RXRX) has a Financial Flexibility Index of -0.26x as of March 2026. Free cash flow of $-80.84 Million (operating CF $-81.10 Million minus capex $258.00K) represents 0% of total liabilities ($314.75 Million). Check Recursion Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Recursion Pharmaceuticals Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Recursion Pharmaceuticals Inc across 7 annual periods. See Recursion Pharmaceuticals Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Recursion Pharmaceuticals Inc (2019–2025)
Year-by-year free cash flow to debt coverage for Recursion Pharmaceuticals Inc. For the full company profile including market capitalisation, see Recursion Pharmaceuticals Inc (RXRX) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.06x | $-365.34 Million | $-371.81 Million | $343.26 Million | ▼ -27.5% |
| 2024 | -0.83x | $-345.48 Million | $-359.17 Million | $413.82 Million | ▲ +42.4% |
| 2023 | -1.45x | $-275.82 Million | $-287.78 Million | $190.26 Million | ▼ -576.7% |
| 2022 | -0.21x | $-46.16 Million | $-83.52 Million | $215.48 Million | ▲ +87.8% |
| 2021 | -1.76x | $-118.82 Million | $-158.61 Million | $67.41 Million | ▼ -2201.7% |
| 2020 | -0.08x | $-38.66 Million | $-45.40 Million | $504.87 Million | ▲ +67.5% |
| 2019 | -0.24x | $-53.13 Million | $-57.04 Million | $225.70 Million | — |